ArriVent BioPharma, Inc. financial data

Industry
Pharmaceutical Preparations
Location
18 Campus Blvd., Suite 100, Newtown Square, Pennsylvania
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.5M shares
Common Stock, Shares, Outstanding 33.5M shares
Common Stock, Value, Issued 3K USD
Weighted Average Number of Shares Outstanding, Basic 25M shares +1845%
Weighted Average Number of Shares Outstanding, Diluted 25M shares +1845%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 17M USD +65.8%
General and Administrative Expense 3.7M USD +91.1%
Operating Income (Loss) -20.7M USD -69.8%
Net Income (Loss) Attributable to Parent -17.4M USD -43.1%
Earnings Per Share, Basic -0.7 USD/shares +92.6%
Earnings Per Share, Diluted -0.7 USD/shares +92.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 317M USD
Assets, Current 327M USD
Operating Lease, Right-of-Use Asset 250K USD
Other Assets, Noncurrent 108K USD
Assets 328M USD
Accounts Payable, Current 4.1M USD
Employee-related Liabilities, Current 1.04M USD
Accrued Liabilities, Current 5.73M USD
Liabilities, Current 9.98M USD
Operating Lease, Liability, Noncurrent 138K USD
Liabilities 10.1M USD
Retained Earnings (Accumulated Deficit) -175M USD
Stockholders' Equity Attributable to Parent 318M USD
Liabilities and Equity 328M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.6M USD -10.3%
Net Cash Provided by (Used in) Financing Activities 186M USD +313%
Common Stock, Shares Authorized 200M shares
Common Stock, Shares, Issued 33.5M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 167M USD +495%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 317M USD +65.8%
Operating Lease, Liability 285K USD
Lessee, Operating Lease, Liability, to be Paid 313K USD
Operating Lease, Liability, Current 147K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 14K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 173K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 493M USD
Share-based Payment Arrangement, Expense 625K USD +277%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares